Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Danaher ( (DHR) ) just unveiled an announcement.
On February 17, 2026, Danaher announced a definitive agreement to acquire Masimo Corporation, a specialty diagnostics company known for pulse oximetry and patient monitoring solutions used primarily in acute care settings. Danaher will pay $180 per share in cash, implying an enterprise value of about $9.9 billion and valuing the deal at roughly 18 times estimated 2027 EBITDA, or 15 times including anticipated synergies.
Masimo will become a standalone operating company within Danaher’s Diagnostics segment, a move expected to strengthen Danaher’s diagnostics franchise with advanced sensor and AI-enabled monitoring technologies. The transaction, slated to close in the second half of 2026 subject to regulatory and shareholder approvals, is projected to be accretive to adjusted earnings, enhance core revenue growth, and deliver significant cost and revenue synergies, underscoring Danaher’s push to expand its position in hospital diagnostics and critical-care decision support.
Under Danaher’s ownership, Masimo is projected to generate more than $530 million in EBITDA in 2027, supported by over $125 million in annual cost synergies and more than $50 million in annual revenue synergies by the fifth full year after closing. Danaher plans to fund the acquisition with cash on hand and debt financing, signaling continued balance-sheet capacity for strategic deals while intensifying competitive pressure in the global diagnostics and patient-monitoring market.
The most recent analyst rating on (DHR) stock is a Buy with a $270.00 price target. To see the full list of analyst forecasts on Danaher stock, see the DHR Stock Forecast page.
Spark’s Take on DHR Stock
According to Spark, TipRanks’ AI Analyst, DHR is a Neutral.
The score is driven primarily by resilient financial quality (strong margins/cash flow and improving leverage) and a generally constructive but cautious FY2026 outlook. Offsetting these positives are weak near-term technicals and a stretched valuation that raises execution sensitivity if growth/margins disappoint.
To see Spark’s full report on DHR stock, click here.
More about Danaher
Danaher Corporation is a leading global life sciences and diagnostics innovator that develops advanced scientific and technology solutions to improve human health. Through a portfolio that includes diagnostics businesses such as Radiometer, Leica Biosystems, Cepheid and Beckman Coulter Diagnostics, Danaher focuses on faster, more accurate diagnosis and supporting the discovery, development and delivery of life‑changing therapies worldwide.
Average Trading Volume: 3,731,405
Technical Sentiment Signal: Sell
Current Market Cap: $150.2B
For a thorough assessment of DHR stock, go to TipRanks’ Stock Analysis page.